OctoPlus' Locteron enters Ph II HCV study
Leiden, Netherlands-based drug delivery specialist OctoPlus says that it has initiated a Phase IIa trial of its drug Locteron, a controlled-release formulation of alfa interferon, as a treatment for chronic hepatitis C infection. The company added that the program is designed to evaluate the safety of the drug in combination with ribavirn in treatment-naive HCV patients.
OctoPlus said that the results of a previously-completed Phase I study demonstrated that the agent, which utilizes the patented PolActive delivery mechanism, was both safe and capable of gradually releasing alfa interferon over a two-week period (Marketletter May 1, 2006). The newly, initiated study is scheduled to run for 12 weeks and will seek to enroll 32 subjects. Results are expected by the middle of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze